News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ReNeuron Says Initial Tests On Stroke Treatment OK
November 18, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Stem-cell firm ReNeuron Group Plc (RENE.L: Quote, Profile, Research) said on Friday that initial tests on its stroke treatment ReNOO1 found it did not form tumours, a factor it says is key for approval to carry out human trials.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
ALS
Novartis halts TREM2 targeting ALS program in 4th
trial stumble in a month
September 16, 2026
·
2 min read
·
Heather McKenzie
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
·
1 min read
·
Jef Akst
Lung cancer
Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
September 15, 2026
·
3 min read
·
Tristan Manalac
Deals
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
September 15, 2026
·
2 min read
·
Gabrielle Masson
